An increased risk of prostate cancer for carriers of mutations in ATM has also been reported, and further investigation is needed to establish the level of increased risk for carriers of mutations in the partner and localizer of BRCA2 (PALB2), nibrin (NBN), and more recently implicated DNA repair genes, such as recombination protein A (RAD) 51, Fanconi anemia complementation group A (FANCA) and BRIP1 (43-49). This evidence concerns the gene PALB2 and prostate carcinoma.